Assembly Biosciences and Arbutus announced collaboration to evaluate combination of core inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in patients with Chronic Hepatitis B Virus Infection
| | |

Assembly Biosciences and Arbutus announced collaboration to evaluate combination of core inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in patients with Chronic Hepatitis B Virus Infection

On Aug. 27, 2020, Assembly Biosciences and Arbutus Biopharma announced that the companies have entered into a clinical…